Literature DB >> 8449079

Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?

C A Wagenvoort1, P G Mulder.   

Abstract

In 78 patients with primary plexogenic arteriopathy (PPA), numbers of organized and recanalized thrombi were established in histologic slides of lung tissue and expressed per square centimeter of section. Three control groups of ten individuals each were used: normal, plexogenic arteriopathy secondary to ventricular septal defect, and hypoxic pulmonary hypertension. Thrombotic lesions were scarce in normal individuals but numerous in all three groups with pulmonary hypertension. There is also a positive correlation with age. Thrombotic lesions are absent or scarce in children but more common in adults, even in normal control subjects and particularly in pulmonary hypertension by whatever cause. In PPA there is likely to be a relation with the duration of illness but not with the stage of the disease. The complete pattern of plexogenic arteriopathy may develop in the absence of thrombotic lesions, which clearly are not essential for its pathogenesis. Rather than being part specifically of PPA, as sometimes suggested, thrombotic lesions complicate various types of hypertensive pulmonary vascular disease. Apparently the combination of sustained pulmonary hypertension and age, possibly through endothelial injury, may elicit thrombosis and its sequelae, which in turn may aggravate the pulmonary arterial pressure.

Entities:  

Mesh:

Year:  1993        PMID: 8449079     DOI: 10.1378/chest.103.3.844

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Thromboembolism in primary pulmonary hypertension.

Authors:  A Bishop; P Oldershaw
Journal:  BMJ       Date:  1996-12-07

Review 2.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Plexogenic arteriopathy.

Authors:  C A Wagenvoort
Journal:  Thorax       Date:  1994       Impact factor: 9.139

4.  Exploration of the pulmonary circulation. Festschrift to Professor Donald Heath.

Authors: 
Journal:  Thorax       Date:  1994       Impact factor: 9.139

5.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

Review 6.  Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.

Authors:  Lynn A Fussner; Michael J Krowka
Journal:  Curr Gastroenterol Rep       Date:  2016-06

7.  Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension.

Authors:  I Chazova; J E Loyd; V S Zhdanov; J H Newman; Y Belenkov; B Meyrick
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

8.  Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension.

Authors:  Thomas A White; Tyra A Witt; Shuchong Pan; Cheryl S Mueske; Laurel S Kleppe; Eric W Holroyd; Hunter C Champion; Robert D Simari
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-31       Impact factor: 6.914

9.  Physiologic and molecular consequences of endothelial Bmpr2 mutation.

Authors:  Susan Majka; Moira Hagen; Thomas Blackwell; Julie Harral; Jennifer A Johnson; Robert Gendron; Helene Paradis; Daniel Crona; James E Loyd; Eva Nozik-Grayck; Kurt R Stenmark; James West
Journal:  Respir Res       Date:  2011-06-22

10.  Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry.

Authors:  Karim Said
Journal:  Glob Cardiol Sci Pract       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.